Relentlessly Focused on Liver Disease

Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFICRead the full press release

Targeted Expertise.
Brighter Outcomes.

There are currently no approved drug therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Our goal is to change that.

LEARN MORE

Backed by Deep Knowledge of IBAT Inhibition

Dedicated to the development of novel bile acid modulators to relieve the pain and suffering of people living with orphan liver diseases.

Read Our Science

Better Pediatric Liver Solutions are in Development

Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology.

View Pipeline

Albireo's odevixibat is a potent and selective IBAT inhibitor

We are developing odevixibat initially to treat patients with PFIC, a rare genetic liver disease.

A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators

We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder.

Download Now

Recent News, Events & Presentations